Overview

Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects

Status:
Completed
Trial end date:
2020-04-03
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, study to assess the safety, tolerability, PK, and PD of multiple oral doses of CIN-107 when administered to healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
CinCor Pharma, Inc.